Abstract
Multi-parameter gene expression assays (MPA) to aid selection of chemotherapy in hormone-sensitive early breast cancer have not been prospectively validated. This field of personalised medicine is rapidly evolving. There is currently no “best test”. OPTIMA is an adaptive trial of MPA-based chemotherapy assignment in a largely node-positive breast cancer population.
Highlights
Multi-parameter gene expression assays (MPA) to aid selection of chemotherapy in hormone-sensitive early breast cancer have not been prospectively validated
OPTIMA is an adaptive trial of MPA-based chemotherapy assignment in a largely node-positive breast cancer population
Funding Project funded by the NIHR HTA Programme (10/34/01)
Summary
Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests. Janet Dunn1*, Andrea Marshall, Amy Campbell, David Cameron, Helena Earl, Iain Macpherson, Christopher Poole, Daniel Rea, Adele Francis, Victoria Harmer, Adrienne Morgan, Nigel Stallard, Andreas Makris, Luke Hughes-Davies, Robert Stein. From 3rd International Clinical Trials Methodology Conference Glasgow, UK. From 3rd International Clinical Trials Methodology Conference Glasgow, UK. 16-17 November 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
